[
  {
    "ts": null,
    "headline": "S&P 500 Edges Down Weekly as Declines Led by Health Care Outweigh Energy-Led Gains",
    "summary": "The Standard & Poor's 500 index edged down 0.2% this week as gains in the energy, technology and fin",
    "url": "https://finnhub.io/api/news?id=752e4339f3052d0b014796e6aba72ccbe768764c241e2f7feeee631dbf260c2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750452244,
      "headline": "S&P 500 Edges Down Weekly as Declines Led by Health Care Outweigh Energy-Led Gains",
      "id": 135445583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Standard & Poor's 500 index edged down 0.2% this week as gains in the energy, technology and fin",
      "url": "https://finnhub.io/api/news?id=752e4339f3052d0b014796e6aba72ccbe768764c241e2f7feeee631dbf260c2e"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
    "summary": "Health care stocks declined late Friday afternoon, with the NYSE Health Care Index and the Health Ca",
    "url": "https://finnhub.io/api/news?id=1720ae676a578cc4d6cffcab65ac1a7194e731352347508c7c5a015fe275e93e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750449776,
      "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
      "id": 135456177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks declined late Friday afternoon, with the NYSE Health Care Index and the Health Ca",
      "url": "https://finnhub.io/api/news?id=1720ae676a578cc4d6cffcab65ac1a7194e731352347508c7c5a015fe275e93e"
    }
  },
  {
    "ts": null,
    "headline": "Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says",
    "summary": "(Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday.  About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite.  Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week.",
    "url": "https://finnhub.io/api/news?id=31e04751efb01a7bf3c2e3b744bcab43803917e4596b88c0d81b6918a1f61ed6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750448742,
      "headline": "Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says",
      "id": 135443728,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday.  About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite.  Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week.",
      "url": "https://finnhub.io/api/news?id=31e04751efb01a7bf3c2e3b744bcab43803917e4596b88c0d81b6918a1f61ed6"
    }
  },
  {
    "ts": null,
    "headline": "A $1.3 Billion Reason to Buy Eli Lilly Stock Now",
    "summary": "Eli Lilly has just acquired gene-editing company Verve Therapeutics.",
    "url": "https://finnhub.io/api/news?id=7c11cb712727ff688f012dc2c1f18498238cff015c7adbe8aa912010a5ed97ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750446002,
      "headline": "A $1.3 Billion Reason to Buy Eli Lilly Stock Now",
      "id": 135456179,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has just acquired gene-editing company Verve Therapeutics.",
      "url": "https://finnhub.io/api/news?id=7c11cb712727ff688f012dc2c1f18498238cff015c7adbe8aa912010a5ed97ca"
    }
  },
  {
    "ts": null,
    "headline": "Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week",
    "summary": "Lilly is acquiring an exciting new program with the agreement to buy Verve Therapeutics.  Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve.",
    "url": "https://finnhub.io/api/news?id=0379ddfafb490cfccccd344871219c9f99452aeae841e5b6115e416b9dc68203",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750439250,
      "headline": "Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week",
      "id": 135446532,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly is acquiring an exciting new program with the agreement to buy Verve Therapeutics.  Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve.",
      "url": "https://finnhub.io/api/news?id=0379ddfafb490cfccccd344871219c9f99452aeae841e5b6115e416b9dc68203"
    }
  },
  {
    "ts": null,
    "headline": "Update: Lilly to Appeal Against UK Regulator's Recommendation Not to Reimburse Cost of Alzheimer's Drug",
    "summary": "(Updates with NICE's response in the fifth and sixth paragraphs and the latest stock movement in the",
    "url": "https://finnhub.io/api/news?id=a6e1c10b81365add54568df6c422239ccc7d1be0dc3a4a1ae525484316588cba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750432882,
      "headline": "Update: Lilly to Appeal Against UK Regulator's Recommendation Not to Reimburse Cost of Alzheimer's Drug",
      "id": 135438369,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Updates with NICE's response in the fifth and sixth paragraphs and the latest stock movement in the",
      "url": "https://finnhub.io/api/news?id=a6e1c10b81365add54568df6c422239ccc7d1be0dc3a4a1ae525484316588cba"
    }
  },
  {
    "ts": null,
    "headline": "Ricks Is the King of Pharma, Thanks to Lilly’s Zepbound",
    "summary": "Under CEO Dave Ricks, 58,  Eli Lilly  seems to have won the weight-loss war.  Lilly’s Danish rival,  Novo Nordisk  had the early advantage, launching its obesity drug Wegovy two years before the Food and Drug Administration approved Lilly’s Zepbound.  Enthusiasm for the stocks was boundless: Lilly shares climbed more than 320% from 2022 to mid-2024, while Novo’s American depositary receipts were up more than 150%.",
    "url": "https://finnhub.io/api/news?id=44ea6cc6295634eda1c9c3639b1af8832e8023740d62bb0ca37b96b5b7272a8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750426200,
      "headline": "Ricks Is the King of Pharma, Thanks to Lilly’s Zepbound",
      "id": 135435330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Under CEO Dave Ricks, 58,  Eli Lilly  seems to have won the weight-loss war.  Lilly’s Danish rival,  Novo Nordisk  had the early advantage, launching its obesity drug Wegovy two years before the Food and Drug Administration approved Lilly’s Zepbound.  Enthusiasm for the stocks was boundless: Lilly shares climbed more than 320% from 2022 to mid-2024, while Novo’s American depositary receipts were up more than 150%.",
      "url": "https://finnhub.io/api/news?id=44ea6cc6295634eda1c9c3639b1af8832e8023740d62bb0ca37b96b5b7272a8f"
    }
  },
  {
    "ts": null,
    "headline": "LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?",
    "summary": "LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.",
    "url": "https://finnhub.io/api/news?id=f49f44d9f96fc714fc464c3c6503193b84e86f883cd405932853921859a4c293",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750426080,
      "headline": "LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?",
      "id": 135435331,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.",
      "url": "https://finnhub.io/api/news?id=f49f44d9f96fc714fc464c3c6503193b84e86f883cd405932853921859a4c293"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=edc5d7ac323921698e0c506912265cc5cefaf7352790c5eb9be0d95fb05f53ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750424405,
      "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 135438377,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=edc5d7ac323921698e0c506912265cc5cefaf7352790c5eb9be0d95fb05f53ae"
    }
  },
  {
    "ts": null,
    "headline": "This AI Trader Bought Meta Stock and Dumped Eli Lilly",
    "summary": "When you’re stumped or don’t have the time or simply don’t want to make the decision, leave it to an AI stockpicker.  The stockpicker has three U.S.-listed exchange-traded funds—they have a combined asset value of roughly $50 million—that it rebalances every month.  Qraft’s momentum fund,  allocates holdings that have performed well in the past based on the assumption that they will keep climbing.",
    "url": "https://finnhub.io/api/news?id=64bf7faee3c191aa2273b045b04f9764db2bd3eec8bfa2d8b492f31e09aff7fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750415640,
      "headline": "This AI Trader Bought Meta Stock and Dumped Eli Lilly",
      "id": 135424367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "When you’re stumped or don’t have the time or simply don’t want to make the decision, leave it to an AI stockpicker.  The stockpicker has three U.S.-listed exchange-traded funds—they have a combined asset value of roughly $50 million—that it rebalances every month.  Qraft’s momentum fund,  allocates holdings that have performed well in the past based on the assumption that they will keep climbing.",
      "url": "https://finnhub.io/api/news?id=64bf7faee3c191aa2273b045b04f9764db2bd3eec8bfa2d8b492f31e09aff7fc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand",
    "summary": "(Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been \"positive\" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.  The U.S.-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion.  Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May, with the drug logging a 60% rise in overall sales between April and May, according to data from research firm PharmaTrac.",
    "url": "https://finnhub.io/api/news?id=32fc8b16d619cf6ca00e9ff023f35cf08e5757c1e1899934f1b1e045b1459b8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750409475,
      "headline": "Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand",
      "id": 135438382,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been \"positive\" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.  The U.S.-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion.  Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May, with the drug logging a 60% rise in overall sales between April and May, according to data from research firm PharmaTrac.",
      "url": "https://finnhub.io/api/news?id=32fc8b16d619cf6ca00e9ff023f35cf08e5757c1e1899934f1b1e045b1459b8f"
    }
  }
]